InMed Pharmaceuticals Announces Selection of IVT Formulation for INM-089 in Treatment of Dry AMD

On February 3, 2025, InMed Pharmaceuticals Inc. (NASDAQ: INM) revealed its decision regarding the selection of an intravitreal (IVT) formulation for INM-089 as a drug candidate. This choice is part of the company’s ongoing development program that targets the treatment of dry age-related macular degeneration (AMD).

Michael Woudenberg, InMed’s Chief Operating Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, expressed optimism about recent data showcasing the successful delivery of INM-089 as an IVT formulation. This provides several advantages for the compound’s continued progression in addressing dry AMD. The IVT formulation, combined with the INM-089 active pharmaceutical ingredient, has exhibited successful delivery to the eye in preclinical studies at doses significantly higher than the projected therapeutic level.

In addition to the successful IVT formulation, InMed has completed a series of dose-ranging in vivo studies. These studies will guide the company in selecting appropriate doses for pivotal preclinical toxicology studies, further advancing the development of INM-089 for the treatment of dry AMD.

Dry AMD, affecting the macula and central vision, is a prevalent eye disease with limited treatment options. Two new treatments for late-stage dry AMD have recently been sanctioned, highlighting the pressing need for effective therapies. InMed’s INM-089 has shown promising preclinical results, including neuroprotection of photoreceptors, improvement in retinal pigment epithelium integrity, and reduction of extracellular auto fluorescent deposits, all crucial in addressing the challenges presented by dry AMD.

InMed Pharmaceuticals is committed to developing a pipeline of proprietary small molecule drug candidates focusing on CB1/CB2 receptors. The company’s programs encompass treatments for Alzheimer’s, ocular, and dermatological conditions, with INM-089 standing out as a potential breakthrough in the field of AMD treatment.

Investors interested in InMed Pharmaceuticals may contact Colin Clancy, the Vice President of Investor Relations and Corporate Communications, to learn more about the company and its innovative programs. The cautionary note included in the disclosure emphasizes the forward-looking information provided, urging due diligence and highlighting the inherent risks and uncertainties associated with such developments.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read InMed Pharmaceuticals’s 8K filing here.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.